Key result
Modest expression of mitochondrial-targeted catalase prevented structural degeneration in Mfn2 null hearts, whereas higher levels super-suppressing ROS failed to improve cardiomyopathy.
Modest suppression of mitochondrial ROS prevents cardiac degeneration in Mfn2 null mice, while supersuppression impairs compensatory autophagy and fails to improve cardiomyopathy, indicating a therapeutic window for ROS suppression.
Answers are grounded in this paper and cite their sources.
Moderate mtROS suppression preserves function in mitophagic cardiomyopathy models; leaves open optimal dosing window before clinical translation.
RATIONALE: Mitochondrial reactive oxygen species (ROS) are implicated in aging, chronic degenerative neurological syndromes, and myopathies. On the basis of free radical hypothesis, dietary, pharmacological, and genetic ROS suppression has been tested to minimize tissue damage, with remarkable therapeutic efficacy. The effects of mitochondrial-specific ROS suppression in primary mitophagic dysfunction are unknown. OBJECTIVE: An in vivo dose-ranging analysis of ROS suppression in an experimental cardiomyopathy provoked by defective mitochondrial clearance. METHODS AND RESULTS: Mice lacking mitofusin 2 (Mfn2) in hearts have impaired parkin-mediated mitophagy leading to accumulation of damaged ROS-producing organelles and progressive heart failure. As expected, cardiomyocyte-directed expression of mitochondrial-targeted catalase at modest levels normalized mitochondrial ROS production and prevented mitochondrial depolarization, respiratory impairment, and structural degeneration in Mfn2 null hearts. In contrast, catalase expression at higher levels that supersuppressed mitochondrial ROS failed to improve either mitochondrial fitness or cardiomyopathy, revealing that ROS toxicity is not the primary mechanism for cardiac degeneration. Lack of benefit from supersuppressing ROS was associated with failure to invoke secondary autophagic pathways of mitochondrial quality control, revealing a role for ROS signaling in mitochondrial clearance. Mitochondrial permeability transition pore function was normal, and genetic inhibition of mitochondrial permeability transition pore function did not alter mitochondrial or cardiac degeneration, in Mfn2 null hearts. CONCLUSIONS: Local mitochondrial ROS (1) contribute to mitochondrial degeneration and (2) activate mitochondrial quality control mechanisms. A therapeutic window for mitochondrial ROS suppression should minimize the former while retaining the latter, which we achieved by expressing lower levels of catalase.
No takes yet. Share an insight, caveat, or question.
Song et al. (2014) studied Experimental cardiomyopathy provoked by defective mitochondrial clearance. Mitochondrial-targeted catalase expression vs. Mfn2 null hearts without catalase was evaluated on Mitochondrial ROS production, mitochondrial depolarization, respiratory impairment, and structural degeneration. Modest expression of mitochondrial-targeted catalase prevented structural degeneration in Mfn2 null hearts, whereas higher levels super-suppressing ROS failed to improve cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: